First-ever in-utero stem cell therapy for fetal spina bifida repair is safe

6 hours ago

First-ever in-utero stem cell therapy for spina bifida repair is safe, according to Phase 1 of the CuRe Trial.
The treatment combines fetal surgery with human placenta-derived stem cells to repair myelomeningocele.
No safety concerns, infections, or abnormal tissue growth were reported in the first six babies treated.
MRI scans showed reversal of hindbrain herniation in all infants, indicating surgical success.
Spina bifida affects 1,500 to 2,000 children annually in the U.S., with many facing lifelong disabilities.
The CuRe Trial aims to improve mobility and quality of life beyond current fetal surgery outcomes.
Phase 1/2a of the trial is now enrolling up to 35 patients, with long-term follow-up planned through age 6.
The study is funded by the California Institute for Regenerative Medicine (CIRM) and Shriners Children’s.

Hasty Briefsbeta